Kircik Leon H, Gwazdauskas Jennifer, Butners Victoria, Eastern Joseph, Green Lawrence J
Indiana University School of Medicine, Indianapolis, IN, USA.
J Drugs Dermatol. 2013 Mar;12(3):259-64.
Benzoyl peroxide (BPO) is a widely used over-the-counter (OTC) topical acne treatment often used in combination with salicylic acid (SA) to achieve better comedone control than that achieved with BPO alone. MaxClarity™ is an OTC acne treatment system comprising BPO and SA in an aqueous foam delivery vehicle, VersaFoam AF™. This paper describes 2 open-label, single-arm studies conducted to assess the efficacy, safety, tolerability, and patient preference of MaxClarity in the treatment of mild, moderate, and severe acne. Subjects applied MaxClarity twice daily for 8 weeks in study 402 and for 12 weeks in study 405. Reductions in all lesion types were seen throughout both studies. At week 8 (study 402), there was a mean reduction from baseline of -56.9 ± 32.7% in total lesions in subjects with mild, moderate, or severe acne. At week 12 (study 405), there was a reduction from baseline of -61.6 ± 22.0% in total lesions in subjects with moderate or severe acne. Overall, both studies demonstrated that MaxClarity is a generally well tolerated and effective treatment for mild, moderate, and severe acne.
过氧化苯甲酰（BPO）是一种广泛使用的非处方（OTC）外用痤疮治疗药物，常与水杨酸（SA）联合使用，以实现比单独使用BPO更好的粉刺控制效果。MaxClarity™是一种OTC痤疮治疗系统，在水性泡沫递送载体VersaFoam AF™中包含BPO和SA。本文描述了两项开放标签、单臂研究，旨在评估MaxClarity在治疗轻度、中度和重度痤疮方面的疗效、安全性、耐受性和患者偏好。在研究402中，受试者每天两次使用MaxClarity，持续8周；在研究405中，持续12周。在两项研究中，所有皮损类型均有减少。在第8周（研究402），轻度、中度或重度痤疮受试者的总皮损数较基线平均减少了-56.9±32.7%。在第12周（研究405），中度或重度痤疮受试者的总皮损数较基线减少了-61.6±22.0%。总体而言，两项研究均表明，MaxClarity对轻度、中度和重度痤疮是一种普遍耐受性良好且有效的治疗方法。
